Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Others Urological ConditionsArchives

Successful Management of Immune-Related Cardiac Adverse Events and Long-term Survival in a Patient with Metastatic Urothelial Carcinoma Treated with Tislelizumab: A Case Report
Others Urological Conditions
 1 min.

 Published on 17/04/2026 |  Original article (Full-text)  | Huiguang Gao et al. | European Heart Journal Supplement. Volume 28(Supplement 2).

Urothelial carcinoma is the most common pathological type of bladder tumor, accounting for approximately 90% of all primary bladder malignancies. Locally advanced or metastatic urothelial carcinoma is generally difficult to cure, and treatment options remain limited. PD-1/PD-L1 immune checkpoint inhibitors...

HTML version PDF version  Print abstract

Urological cancer risk in patients with rheumatoid arthritis compared to matched controls: a nationwide cohort study
Others Urological Conditions
 1 min.

 Published on 10/04/2026 |  Original article (Full-text)  | Dagyeong Lee et al. | Rheumatology. Volume 64(6).

Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with several comorbidities, including an increased risk of certain cancers. This study aimed to investigate the potential associations between RA and increased risk of urological cancers - specifically kidney, bladder, prostate and...

HTML version PDF version  Print abstract

Reduced activin A levels impair urogenital system development and compromise female mouse fertility
Others Urological Conditions
 1 min.

 Published on 03/04/2026 |  Original article (Full-text)  | Eliza Winek et al. | Molecular Human Reproduction. Volume 32(1).

Activin A, encoded by the Inhba gene, is a versatile protein crucial for numerous biological processes, and its dysregulation is implicated in various human disorders. However, the perinatal lethality of Inhba knockout mice restricts the delineation of the full extent of this protein's function in the...

HTML version PDF version  Print abstract

Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort study
Others Urological Conditions
 1 min.

 Published on 27/03/2026 |  Original article (Full-text)  | Kosuke Iwatani et al. | Japanese Journal of Clinical Oncology. Volume 56(2).

Enfortumab vedotin plus pembrolizumab (EVP) has shown promising efficacy in locally advanced or metastatic urothelial carcinoma (la/mUC), but real-world data in Japanese patients are limited. We assessed the safety and early efficacy of EVP, with a focus on cutaneous adverse events (AEs). Methods: We...

HTML version PDF version  Print abstract

Neoadjuvant immune checkpoint inhibitors for muscle-invasive urothelial carcinoma: a systematic review and meta-analysis
Others Urological Conditions
 1 min.

 Published on 20/03/2026 |  Original article (Full-text)  | Ana Luíza Rocha Soares Menegat et al. | Immunotherapy 2026; aop:10.1080/1750743X.2026.2643128

Muscle-invasive urothelial carcinoma (MIUC) represents one-quarter of cancers and carries morbidity and mortality. Although cisplatin neoadjuvant chemotherapy plus radical cystectomy improves survival, patients may be ineligible due to renal dysfunction or comorbidities. Immune checkpoint inhibitors...

HTML version PDF version  Print abstract